Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
In 2019, nintedanib became the first therapy approved by the FDA to slow the rat···【more】
Release date：2026-02-03Recommended：112
Nintedanib is a small-molecule tyrosine kinase inhibitor that binds to growth fa···【more】
Release date：2026-02-03Recommended：94
Nintedanib is indicated for the treatment of diseases that cause scarring and ha···【more】
Release date：2026-02-03Recommended：107
Elacestrant is the world’s first approved oral selective estrogen receptor degra···【more】
Release date：2026-02-02Recommended：107
Before starting elacestrant, discuss any questions or concerns with your medical···【more】
Release date：2026-02-02Recommended：130
Take elacestrant daily and always follow the guidance of your medical team stric···【more】
Release date：2026-02-02Recommended：112
Elacestrant is indicated for the treatment of postmenopausal women or adult men ···【more】
Release date：2026-02-02Recommended：123
Anagrelide is indicated to reduce the risk of blood clots in patients with throm···【more】
Release date：2026-01-30Recommended：80
Special caution is required when using anagrelide, as certain drugs may interact···【more】
Release date：2026-01-30Recommended：63
Anagrelide may cause a range of side effects during use.What side effects may An···【more】
Release date：2026-01-30Recommended：74
Anagrelide is used to reduce the platelet count in patients with myeloproliferat···【more】
Release date：2026-01-30Recommended：64
Revumenib (Revuforj) is an oral, first-in-class targeted Menin protein inhibitor···【more】
Release date：2026-01-29Recommended：118
